2016
DOI: 10.1016/j.jclinane.2015.08.015
|View full text |Cite
|
Sign up to set email alerts
|

A report on the consequences of the first implanted device for long-term analgesia in refractory cancer pain

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2017
2017
2021
2021

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 18 publications
0
2
0
Order By: Relevance
“…The first intrathecal use of bolus morphine for cancer pain analgesia was described by Wang in 1979 and in 1980 intrathecal analgesia for pancreatic cancer pain was described by Tung (91,92). Neuraxial infusion systems have now been available for more than 40 years (93). Since these seminal studies were published, they have confirmed that this is an appreciated option for the small proportion of highly distressed cancer patients who have exhausted all other analgesic treatments.…”
Section: Intrathecal Drug Delivery For Pcrpmentioning
confidence: 99%
“…The first intrathecal use of bolus morphine for cancer pain analgesia was described by Wang in 1979 and in 1980 intrathecal analgesia for pancreatic cancer pain was described by Tung (91,92). Neuraxial infusion systems have now been available for more than 40 years (93). Since these seminal studies were published, they have confirmed that this is an appreciated option for the small proportion of highly distressed cancer patients who have exhausted all other analgesic treatments.…”
Section: Intrathecal Drug Delivery For Pcrpmentioning
confidence: 99%
“…For these patients, outcomes relating to pain and quality of life have been observed to have improved. (5,6). Cancer pain treatment guidelines now include this therapy as an alternative for Copyright 2020 KEI Journals.…”
Section: Introductionmentioning
confidence: 99%